Pramlintide
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
AstraZeneca · Phase 2 · Completed · Enrollment 258
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| 1 | n/r | n/r | n/r | n/r | n/r |
| 2 | n/r | n/r | n/r | n/r | n/r |
| 3 | n/r | n/r | n/r | n/r | n/r |
| 4 | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.